Abstract
Despite the recent advances in cancer therapeutics for lymphoma (Lym), a continuum of disease, treatment and psychological challenges, adversely impacting health-related quality of life, remain for the clinical management of the patient with Lym. In response, this study presents the development and validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18). Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist-oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in Lym for instrument development. Reliability estimates indicate that FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced Lym in the clinical trial research environment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1942-1946 |
| Number of pages | 5 |
| Journal | Leukemia and Lymphoma |
| Volume | 54 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2013 |
Fingerprint
Keywords
- FLymSI-18
- HRQOL
- Lymphoma
- Symptom Index
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
}
A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma : The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index. / Hlubocky, Fay J.; Webster, Kimberly A; Beaumont, Jennifer; Cashy, John; Paul, Diane; Abernethy, Amy; Syrjala, Karen L.; Von Roenn, Jamie; Cella, David.
In: Leukemia and Lymphoma, Vol. 54, No. 9, 01.09.2013, p. 1942-1946.Research output: Contribution to journal › Article
TY - JOUR
T1 - A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma
T2 - The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index
AU - Hlubocky, Fay J.
AU - Webster, Kimberly A
AU - Beaumont, Jennifer
AU - Cashy, John
AU - Paul, Diane
AU - Abernethy, Amy
AU - Syrjala, Karen L.
AU - Von Roenn, Jamie
AU - Cella, David
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Despite the recent advances in cancer therapeutics for lymphoma (Lym), a continuum of disease, treatment and psychological challenges, adversely impacting health-related quality of life, remain for the clinical management of the patient with Lym. In response, this study presents the development and validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18). Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist-oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in Lym for instrument development. Reliability estimates indicate that FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced Lym in the clinical trial research environment.
AB - Despite the recent advances in cancer therapeutics for lymphoma (Lym), a continuum of disease, treatment and psychological challenges, adversely impacting health-related quality of life, remain for the clinical management of the patient with Lym. In response, this study presents the development and validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index-18 (FLymSI-18). Patients with advanced Lym (n = 50) rated the significance of 40 symptoms, and hematologist-oncologists (n = 10) rated these symptoms according to importance and disease-related or treatment-related origin. Patient symptom priorities were unified with clinician priorities for symptom measurement in Lym for instrument development. Reliability estimates indicate that FLymSI-18 has acceptable internal consistency (α = 0.87), content validity and concurrent validity as indicated by moderate to strong correlations with the FACIT (Functional Assessment of Chronic Illness Therapy). Overall, the FLymSI-18 provides evidence for its reliability and validity as a brief assessment of the most important symptoms associated with advanced Lym in the clinical trial research environment.
KW - FLymSI-18
KW - HRQOL
KW - Lymphoma
KW - Symptom Index
UR - http://www.scopus.com/inward/record.url?scp=84882985462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882985462&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.762977
DO - 10.3109/10428194.2012.762977
M3 - Article
VL - 54
SP - 1942
EP - 1946
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 9
ER -